EyeGate Pharmaceuticals Inc (EYEG.OQ)
23 Feb 2018
Get access to over 18 million research reports from over 1,700 sources.
For several years, Reuters.com has provided analyst research reports for downloading. In an effort to streamline our website, analyst research will now be available from our dedicated page for Thomson Reuters On Demand, and the Reuters service will discontinue as of September 30, 2016.
Thomson Reuters On Demand provides over 18 million research reports from 1,700 sources.
Moreover, Thomson Reuters On Demand offers fast and cost-effective solutions that would allow you to retrieve information on:
- private equity
- third-party document and information retrieval
- and much, much more…
Click here to request a report and the team of expert analysts will get back to you shortly, to ensure you get the report you need.
- BRIEF-Eyegate Announces Top-Line Results For Phase 2B Trial Of EGP-437 In Cataract Surgery
- BRIEF-Eyegate Promotes Sarah Romano To CFO
- BRIEF-EyeGate Achieves 75 Pct Enrollment In Pivotal Phase 3 Clinical Trial For Anterior Uveitis Triggering Milestone Payment
- BRIEF-Eyegate Pharmaceuticals posts Q3 net loss $4.1 mln vs $3.4 mln a year ago
- BRIEF-EyeGate completes enrollment in phase 2b clinical trial of EGP-437 for cataract surgery